Cortechs.ai | A word from the CEO: 2015 in review

A word from the CEO: 2015 in review

NeuroQuant_2015_infographic1.png2015 was an incredible year for Cortechs.ai, with the team continuing to build on the momentum we started in 2014. During the year, we experienced remarkable growth in our business, added many significant new customers and expanded our strategic business partnerships.

With over 100,000 brains analyzed using NeuroQuant, it is exciting to watch the growth indicating an increased acceptance and realized importance of using quantitative imaging for the assessment of neurological disorders. During 2015, we established NeuroQuant as the most proven and most accurate quantitative imaging solutions and enjoyed worldwide support within hospitals, universities, radiology centers, clinical and research practices and military hospitals. These facilities see and understand the value of NeuroQuant’s volumetric measurements of subcortical structures aiding in the assessment of a variety of clinical disciplines, from dementia, through epilepsy, multiple sclerosis, traumatic brain injuries and brain development.

In the middle of 2015 we released NeuroQuant 2.0, providing significant additions and improvements, among them, new and improved output reports for ages 3 years to 100, the advanced Dynamic Atlas™ segmentation and registration technology, increased accuracy and precision of brain segmentation, and operating system independence. Toward the end of 2015, we expanded NeuroQuant 2.0 to include productivity enhancing capabilities such as the use of parallel imaging on GE, Philips and Siemens 3.0 T scanners, providing faster scan times, the addition of Toshiba Titan 3T scanner compatibility and PowerScribe 360 integration. Click on the infographic to the right to see a better overall picture of 2015’s developments

With these expanded capabilities NeuroQuant continues to be the paramount solution for the assessment of neurological conditions. From brain development to Alzheimer’s, multiple sclerosis, epilepsy and brain trauma, NeuroQuant helps enhance the quality of patient care. As always, we welcome feedback and ideas for improvement from anybody that wants to share it with us.

2015 was a great year, and we are thrilled to see what unfolds for 2016. Stay tuned – more exciting developments are happening and we look forward to sharing them with you!

Guri Stark, CEO
Cortechs.ai

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top